Business Context and Reporting Period
Penumbra, Inc. (PEN) filed a Form 8-K on January 14, 2026, announcing the entry into a definitive Agreement and Plan of Merger with Boston Scientific Corporation ("Parent"). Under the agreement, Penumbra will merge with a wholly-owned subsidiary of Boston Scientific, with Penumbra surviving as a wholly-owned subsidiary. The filing also references preliminary financial results for the fiscal quarter and year ended December 31, 2025, issued on January 15, 2026.
Key Financial Metrics and Merger Consideration
The filing details the consideration for Penumbra shareholders but does not provide specific revenue, profit, or cash flow figures for the period ended December 31, 2025, as the audited financial statements are not yet available. The preliminary results are estimates subject to finalization.
Merger Consideration Structure:
- Cash Component: $374.00 per share for shareholders electing cash.
- Stock Component: 3.8721 shares of Boston Scientific common stock per Penumbra share for shareholders electing stock.
- Proration: The total consideration will be prorated such that 73.26% of outstanding shares receive cash and 26.74% receive stock, regardless of individual shareholder elections.
- Equity Awards: Options and RSUs will be converted into a mix of cash ($274.00 per share equivalent) and Boston Scientific stock (1.0353 shares per share equivalent), subject to specific vesting and tax withholding rules.
Material Changes and Transaction Terms
The primary material change is the proposed acquisition of Penumbra by Boston Scientific. Key terms include:
- Termination Fees: Penumbra must pay a $525 million fee to Boston Scientific if it terminates the agreement to accept a superior proposal or changes its recommendation. Boston Scientific must pay a $900 million fee to Penumbra if the deal fails due to antitrust issues or legal injunctions after stockholder approval is obtained.
- Delisting: Penumbra securities will be delisted from the NYSE and deregistered under the Exchange Act upon closing.
- No Financing Condition: The merger is not subject to a financing condition.
Guidance, Outlook, and Risks
Conditions to Closing: The transaction is subject to customary conditions, including Penumbra stockholder approval, expiration of antitrust waiting periods (Hart-Scott-Rodino), receipt of required governmental consents, effectiveness of the Form S-4 registration statement, and NYSE listing approval for the stock consideration.
Risks and Contingencies:
- Failure to obtain stockholder or regulatory approvals.
- Disruption to business operations and retention of key personnel during the pendency of the transaction.
- Uncertainty regarding the long-term value of Boston Scientific stock.
- Potential litigation related to the transaction.
- Failure to realize anticipated synergies or benefits.
Management Commentary: The filing includes standard forward-looking statements cautioning that actual results may differ materially from expectations due to various risks. No specific operational guidance for 2026 is provided as the company will become a subsidiary.
Investor Verification Checklist
- Verify the final audited financial results for the year ended December 31, 2025, when the Form 10-K is filed, as current figures are preliminary estimates.
- Review the upcoming Proxy Statement/Prospectus (Form S-4) for detailed risk factors, voting procedures, and the full text of the Merger Agreement.
- Confirm the status of antitrust regulatory approvals and the expiration of the Hart-Scott-Rodino waiting period.
- Monitor the outcome of the Penumbra stockholder vote required to approve the Merger Agreement.
- Understand the specific tax implications of the cash vs. stock election and the proration mechanism affecting individual holdings.